CAH Cardinal Health, Inc. Common Stock
NYSE · Health Care · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 11, 2026CAH Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
CAH Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 23 de abril de 2001 | 3-for-2 | Adelante |
| 2 de noviembre de 1998 | 3-for-2 | Adelante |
| 17 de diciembre de 1996 | 3-for-2 | Adelante |
| 1 de julio de 1994 | 5-for-4 | Adelante |
| 1 de octubre de 1991 | 5-for-4 | Adelante |
| 1 de octubre de 1990 | 5-for-4 | Adelante |
| 2 de octubre de 1989 | 5-for-4 | Adelante |
| 9 de septiembre de 1988 | 11-for-10 | Adelante |
| 9 de septiembre de 1987 | 11-for-10 | Adelante |
Acerca de Cardinal Health, Inc. Common Stock Descripción general de la empresa de Wikipedia
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
History
Founded in 1971 as Cardinal Foods by Robert D. Walter, the company was initially a food wholesaler. After acquiring the Bailey Drug Company in 1979, it began whole selling drugs. The company went public on the NASDAQ stock exchange in 1983.
In 1988, Walter sold Cardinal Health's food operations to Roundy's. From 1991 to 1996, the company's sales grew from $1.2 billion to $8.9 billion. The company changed its name to Cardinal Health in 1994, and became the third-largest pharmaceutical wholesaler in the United States.
2000–2019
R. Kerry Clark, a former executive and vice chairman at Procter & Gamble, was appointed president and CEO in April 2006, with Robert D. Walter retaining Chairmanship of the board. In September 2008, the company announced Clark and Walter would retire and George S. Barrett would become the chairman and CEO.
In 2009, Cardinal Health completed the spin-off of its clinical and medical products businesses into an independent medical technology company called CareFusion with David Schlotterbeck as CEO. Cardinal Health is now traded on the NYSE under symbol CAH.
In December 2013, it was announced that Cardinal Health would partner with CVS Caremark to form a generic drug sourcing operation in the United States. The venture was named Red Oak Sourcing and began operations in July 2014.
Between 2014 and 2016, Cardinal, alongside McKesson Corporation, and AmerisourceBergen, spent $13 million lobbying Congress to pass Congressman Tom Marino's "Ensuring Patient Access and Effective Drug Enforcement Act". The bill, which increases the burden of proof enforcers need to show against drug distributors, was signed into law by President Barack Obama in April 2016.
In January 2018, Michael Kaufmann assumed the role of CEO after serving as CFO of the company.
Opioid lawsuits
In 2019, Cardinal was one of several drug distributors named in lawsuits related to the opioid crisis in the US. In July 2021, Cardinal Health and other pharmaceutical companies agreed to participate in a $26 billion settlement. Cardinal will pay $6.4 billion over 18 years.
In May 2020, Oklahoma Attorney General Mike Hunter sued Cardinal Health in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against AmerisourceBergen and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."
2020–present
As of August 2021, it is ranked 14 on the Fortune 500 list with FY2020 annual revenue of $152.9 billion. The firm employs 57,000 people worldwide.
Acquisitions
In 1995, Medicine Shoppe International, the country's largest franchiser of retail pharmacies, was acquired. The merger represented the first non-distribution acquisition by Cardinal Health.
In 1996, Cardinal Health acquired Pyxis Corporation, a company that developed automated pill dispensers for hospitals, for $867 million.
In 1997, Cardinal Health planned to purchase Bergen Brunswig Corp., to which McKesson Corporation responded with a bid to purchase Amerisource. Instead, Amerisource and Bergen merged into AmerisourceBergen. Later that year, Cardinal Health completed the acquisition of Owen Healthcare, the second-largest provider of pharmacy management services in the U.S. at the time.
In 1999, the firm acquired the Chicago-based medical products manufacturer and distributor, Allegiance Healthcare (formerly a division of Baxter Healthcare). In 2001, the company acquired Bindley Western Industries, a wholesale distributor of pharmaceuticals based in Indianapolis.
In April 2006, Cardinal Health purchased Niagara Falls-based ParMed Pharmaceuticals for $40.1 million. In June 2007, the firm announced the completion of a tender offer for VIASYS Healthcare.
In June 2010, Cardinal Health announced plans to purchase Healthcare Solutions Holding, a specialty pharmaceutical services company, for $517 million. In December 2010, the company acquired Kinray, an independent pharmaceutical wholesaler, increasing Cardinal Health's presence in the independent pharmacy market by 40 percent. From 2010 to 2014, Cardinal Health acquired 18 companies including Yong Yu, a Chinese drug distributor. Cardinal sold Yong Yu in 2017 to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion.
On March 18, 2013, Cardinal Health acquired the Twinsburg, Ohio-based privately held medical supply distributor AssuraMed, and with it its subsidiaries including Edgepark Medical Supplies, for $2.7 billion. AssuraMed was backed by private equity firms Clayton, Dubilier & Rice and Goldman Sachs Alternatives.
In July 2014, Cardinal Health and CVS formed Red Oak Sourcing, the largest generic drug sourcing operation in the United States. The companies started buying generic drugs around the world to sell in U.S. markets.
In March 2015, Cardinal Health signed an agreement to acquire Johnson & Johnson's Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion.
In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017.
In November 2024, Cardinal Health announced the plan to acquire Advanced Diabetes Supply Group (ADSG), a leading national direct-to-patient provider of diabetes medical supplies, for about $1.1 billion with plans to merge the company into its at-Home Solutions business. The at-Home Solutions business includes Edgepark Medical Supplies of Twinsburg, Ohio and United States Medical Supply (US MED) of Doral, Florida. The acquisition was complete by April 2024.
In August 2025, Cardinal Health announced that it would acquire a 75% stake in Solaris Health, the largest urology management services organization (MSO) in the United States, for $1.9 billion in cash.
In July 2026, Cardinal Health agreed to acquire AdaptHealth's diabetes health business and medical-supply provider Strive Medical in separate transactions worth approximately US$360 million in total. The acquisitions were intended to expand its at-Home Solutions business in diabetes and urological care.
Controversy
Role in the Opioid epidemic
Multiple legal settlements have demonstrated Cardinal Health's role in the US Opioid epidemic, though the company never admitted wrongdoing:
December 2016: Cardinal Health settled for $44 million for violations of the Controlled Substances Act brought in allegations from United States Attorneys in districts from Maryland, New York, Florida and Washington.
July 2021: Cardinal Health agreed to pay $6.4 billion to settle thousands of US lawsuits. They were one of four companies to pay $26 billion, including Johnson & Johnson, AmerisourceBergen and McKesson.
May 2022: Settled a derivative suit on behalf of shareholders for $124 million.
August 2024: Settlement with various health plans including insurers and third-party payers for $92.7 million.
August 2024: Settlement with the City of Baltimore for $152.5 million.
Restatements
In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope."
FDA action
In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009.
DEA investigation into Oxycodone diversion
In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone.
Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that it blocked two of the pharmacies, (Brooks Pharmacy in Bonita Springs, Florida, and Gulf Coast Medical in Panama City, Florida), and notified the corporate owners of the two pharmacies that were part of national chains, two CVS stores in Sanford, Florida.
In February 2012, Joseph Rannazzisi, chief of the Drug Enforcement Administration’s Office of Diversion Control, issued immediate suspension orders against Cardinal's supply of oxycodone to suspected pill mills. These orders were filed after Deputy Attorney General James M. Cole met with Rannazzisi to ask if he had met with Cardinal about the investigation. Cole stated that he believed “it made good sense to listen to what Cardinal had to say” regarding the investigation. That year, Cardinal and the DEA reached a settlement that suspended Cardinal's facility in Lakeland, Florida from selling pain killers or other drugs for two years. In 2016, Cardinal was fined $44 million for after the investigation concluded.
In January 2022, Cardinal Health, Johnson & Johnson, McKesson, and AmerisourceBergen agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.
Finances
Annual financial statistics are displayed below:
Cardinal Health Foundation
The Cardinal Health Foundation is the charitable arm of Cardinal Health. The company makes annual product donations of over $9 million through international relief organizations and provides up to $1,000 in matching funds for every Cardinal Health employee that makes a charitable donation. In 2008, the foundation established its E3 Grant Program. Over the past seven years, the Foundation has invested more than $7.15 million in funding to 241 hospitals, health systems or other health-related organizations.
Cardinal Health also supports organizations such as Ronald McDonald House Charities, and was named Benefactor of the Year at the 2011 Corporate Caring Awards. In 2015, the foundation contributed $3 million to the Solutions for Patient Safety project, which has raised over $11 million nationally for efforts to improve safety initiatives in children's hospitals.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | CAH | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | 32.9promedio 5A ≈29.4 | ≈29.4 | 22.9 | Sobrevalorado | |
| PEG Ratio (Ratio PEG) | ≈1.2 | · | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | CAH | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Bruto (TTM) | 3.8%promedio 5A ≈3.5% | ≈3.5% | 4.3% | Débil | |
| Margen Operativo (TTM) | 1.0%promedio 5A ≈0.52% | ≈0.52% | 1.1% | En línea | |
| Margen EBITDA (TTM) | 1.4%promedio 5A ≈0.88% | ≈0.88% | 1.3% | En línea | |
| Margen antes de impuestos (TTM) | 0.86%promedio 5A ≈0.44% | ≈0.44% | 1.0% | Por debajo del promedio | |
| Margen de Beneficio Neto (TTM) | 0.67%promedio 5A ≈0.27% | ≈0.27% | 0.63% | En línea | |
| ROA | 3.1%promedio 5A ≈1.3% | ≈1.3% | 3.1% | En línea | |
| ROE | -60.5%promedio 5A ≈-65.5% | ≈-65.5% | -4.6% | Débil | |
| ROIC | -71.1%promedio 5A ≈-13.6% | ≈-13.6% | 12.2% | Débil |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | CAH | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 0.9promedio 5A ≈1.0 | ≈1.0 | 0.9 | Baja liquidez | |
| Quick Ratio (Ratio Rápido) | 0.4promedio 5A ≈0.5 | ≈0.5 | 0.5 | Baja liquidez | |
| Interest Coverage (Cobertura de Intereses) | 7.5promedio 5A ≈9.3 | ≈9.3 | 5.9 | Liquidez sólida |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | CAH | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 14.2%promedio 5A ≈9.5% | ≈9.5% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | 7.4%promedio 5A ≈9.1% | ≈9.1% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 9.4% | · | · | · | |
| EPS YoY (EPS interanual) | 12.1%promedio 5A ≈91.0% | ≈91.0% | · | · | |
| Net Income YoY (Beneficio Neto interanual) | 9.8%promedio 5A ≈83.7% | ≈83.7% | · | · | |
| EPS CAGR 3Y (CAGR BPA 3A) | 79.0% | · | · | · | |
| EPS CAGR 5Y (CAGR BPA 5A) | 28.3% | · | · | · | |
| Net Income CAGR 3Y (CAGR Beneficio Neto 3A) | 73.2% | · | · | · | |
| Net Income CAGR 5Y (CAGR Beneficio Neto 5A) | 22.9% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | CAH | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 4.6promedio 5A ≈4.6 | ≈4.6 | 4.5 | De primer nivel | |
| Inventory Turnover (Rotación de Inventario) | 14.3promedio 5A ≈13.2 | ≈13.2 | 15.7 | Débil | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 18.8promedio 5A ≈18.6 | ≈18.6 | 13.1 | De primer nivel | |
| Revenue / Employee (Ingresos / Empleado) | ≈$4.3M | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años
| Fecha ex-dividendo | Monto | Moneda | Rendimiento |
|---|---|---|---|
| Oct 1, 2026 | $0,52 | USD | ≈0.89% |
| Jul 1, 2026 | $0,52 | USD | ≈0.86% |
| Abr 1, 2026 | $0,51 | USD | ≈0.96% |
| Ene 2, 2026 | $0,51 | USD | ≈0.99% |
| Oct 1, 2025 | $0,51 | USD | ≈1.3% |
| Jul 1, 2025 | $0,51 | USD | ≈1.2% |
| Abr 1, 2025 | $0,51 | USD | ≈1.5% |
| Ene 2, 2025 | $0,51 | USD | ≈1.7% |
| Oct 1, 2024 | $0,51 | USD | ≈1.8% |
| Jul 1, 2024 | $0,51 | USD | ≈2.1% |
| Mar 28, 2024 | $0,50 | USD | ≈1.8% |
| Dic 29, 2023 | $0,50 | USD | ≈2.0% |
| Oct 2, 2023 | $0,50 | USD | ≈2.3% |
| Jun 30, 2023 | $0,50 | USD | ≈2.1% |
| Mar 31, 2023 | $0,50 | USD | ≈2.6% |
| Dic 30, 2022 | $0,50 | USD | ≈2.6% |
| Sep 30, 2022 | $0,50 | USD | ≈3.0% |
| Jun 30, 2022 | $0,50 | USD | ≈3.8% |
| Mar 31, 2022 | $0,49 | USD | ≈3.5% |
| Dic 31, 2021 | $0,49 | USD | ≈3.8% |
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 31 de diciembre de 2026 | Ago 11, 2026 | $2.91 | $2.44 | 19.1% |
| 30 de junio de 2026 | $2.60 | $2.44 | 6.4% | |
| 31 de marzo de 2026 | $3.17 | $2.82 | 12.6% | |
| 31 de diciembre de 2025 | $2.63 | $2.40 | 9.4% | |
| 30 de septiembre de 2025 | $2.55 | $2.20 | 15.9% | |
| 30 de junio de 2025 | $2.08 | $2.06 | 1.1% | |
| 31 de marzo de 2025 | $2.35 | $2.19 | 7.4% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Cost of Revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B | $115.00B | $96.82B | |
| Gross Profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | |
| SG&A Expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B | $3.65B | $3.24B | |
| Operating Income | $2.61B | $2.27B | $1.24B | $752M | $-607M | $472M | $-4.10B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | |
| Interest Expense | $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | |
| Other Non-op | $31M | $41M | $9M | $-5M | $-22M | $47M | $1M | $-15M | $-23M | $5M | $-5M | $7M | |
| Pretax Income | $2.17B | $2.10B | $1.20B | $663M | $-784M | $323M | $-3.77B | $1.75B | $-228M | $1.92B | $2.28B | $1.97B | |
| Income Tax | $469M | $532M | $348M | $332M | $153M | $-289M | $-79M | $386M | $-487M | $630M | $845M | $755M | |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| EPS (Basic) | $7.27 | $6.48 | $3.48 | $1.27 | $-3.37 | $2.09 | $-12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | |
| EPS (Diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | |
| Shares (Basic) | 236,000,000 | 241,000,000 | 245,000,000 | 261,000,000 | 279,000,000 | 292,000,000 | 293,000,000 | 300,000,000 | 313,000,000 | 317,000,000 | 327,000,000 | 332,000,000 | |
| Shares (Diluted) | 237,000,000 | 242,000,000 | 247,000,000 | 262,000,000 | 279,000,000 | 294,000,000 | 293,000,000 | 301,000,000 | 315,000,000 | 320,000,000 | 330,000,000 | 335,000,000 | |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.42B | $96M | $1.25B | $-3.19B | $3.06B | $1.16B | $2.84B | $3.10B | $2.61B |
Balance general
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B | $2.36B | $4.62B | |
| Short-term Investments | · | · | $200M | · | · | · | · | · | · | $65M | $113M | $91M | |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B | $7.41B | $6.52B | |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B | $10.62B | $9.21B | |
| Other Current Assets | $2.76B | $2.41B | $2.66B | $2.29B | $2.02B | $2.84B | $1.71B | $1.95B | $1.93B | $2.12B | $1.58B | $1.40B | |
| Current Assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B | $21.96B | $21.75B | |
| PP&E (Net) | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B | $1.80B | $1.51B | |
| PP&E (Gross) | $7.97B | $7.52B | $6.70B | $6.31B | $5.88B | $5.59B | $5.33B | $5.17B | $5.26B | $4.63B | $4.48B | $4.03B | |
| Accum. Depreciation | $4.93B | $4.66B | $4.17B | $3.85B | $3.52B | $3.23B | $2.96B | $2.81B | $2.77B | $2.75B | $2.68B | $2.53B | |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B | $7.17B | $5.07B | |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B | $1.99B | $948M | |
| Other Non-current Assets | $1.88B | $1.71B | $1.26B | $1.07B | $953M | $951M | $1.19B | $1.05B | $682M | $681M | $944M | $866M | |
| Total Assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B | |
| Accounts Payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B | $17.31B | $14.37B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | $0 | |
| Current Liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B | $19.70B | $17.24B | |
| Capital Leases | $861M | $654M | $400M | $375M | $388M | $374M | $341M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $1.75B | $1.81B | $1.95B | $1.70B | $328M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | · | |
| Common Stock | $2.89B | $2.96B | $2.92B | $2.75B | $2.81B | $2.81B | $2.79B | $2.76B | $2.73B | $2.70B | $3.01B | $3.00B | |
| Retained Earnings | $2.01B | $783M | $-286M | $-642M | $-280M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B | $6.42B | $5.52B | |
| Treasury Stock | $7.61B | $6.37B | $5.68B | $4.91B | $3.13B | $2.19B | $2.07B | $1.79B | $1.22B | $731M | $2.76B | $2.25B | |
| AOCI | $-165M | $-155M | $-167M | $-151M | $-114M | $-34M | $-104M | $-79M | $-92M | $-125M | $-116M | $-23M | |
| Stockholders' Equity | $-2.88B | $-2.78B | $-3.21B | $-2.96B | $-709M | $1.79B | $1.79B | $6.33B | $6.06B | $6.81B | $6.55B | $6.26B | |
| Liabilities + Equity | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B |
Flujo de Efectivo
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1.00B | $1.03B | $717M | $641M | $451M | |
| Stock-based Comp | $367M | $244M | $121M | $96M | $81M | $89M | $90M | $82M | $85M | $96M | $111M | $110M | |
| Deferred Tax | $91M | $243M | $-104M | $-40M | $14M | $496M | $-961M | $-83M | $-1.01B | $291M | $87M | $219M | |
| Amort. of Intangibles | $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | |
| Restructuring | $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | |
| Other Non-cash | $2.05B | $-441M | $2.18B | $1.82B | $3.27B | $450M | $5.61B | $360M | $2.41B | · | $705M | $545M | |
| Operating Cash Flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B | $2.97B | $2.54B | |
| CapEx | $649M | $547M | $511M | $481M | $387M | $400M | $375M | $328M | $384M | $387M | $465M | $300M | |
| Investing Cash Flow | $-2.58B | $-5.59B | $-1.85B | $-454M | $567M | $-378M | $493M | $338M | $-5.61B | $-405M | $-4.08B | $-849M | |
| Debt Issued | $1.00B | $2.90B | $1.14B | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $347M | $2.46B | $357M | $-579M | $-885M | $-570M | $-1.40B | $-1.10B | $-954M | $-310M | $-6M | $-1.22B | |
| Stock Repurchased | $1.36B | $765M | $750M | $2.00B | $1.00B | $200M | $350M | $600M | $550M | $600M | $651M | $1.04B | |
| Net Stock Activity | $-1.36B | $-765M | $-750M | $-2.00B | $-1.00B | $-200M | $-350M | $-600M | $-550M | $-600M | $-651M | $-1.04B | |
| Dividends Paid | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M | |
| Financing Cash Flow | $-1.60B | $1.94B | $-847M | $-3.05B | $-2.46B | $-1.32B | $-2.20B | $-2.29B | $-2.28B | $3.75B | $-1.14B | $60M | |
| Net Change in Cash | $982M | $-1.26B | $1.06B | $-669M | $1.36B | $636M | $240M | $768M | $-5.12B | $4.52B | $-2.26B | $1.75B | |
| Taxes Paid | $338M | $444M | $191M | $156M | $-766M | $273M | $368M | $311M | $425M | $686M | $635M | $529M | |
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B | $797M | $2.51B | $2.24B | |
| Levered FCF | $4.25B | $1.69B | $3.21B | $2.32B | $2.55B | $1.69B | $1.35B | $2.16B | $2.76B | $662M | $2.39B | $2.15B |
Rentabilidad
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% | 4.5% | 4.7% | 5.2% | 5.0% | 5.4% | 5.6% | |
| Operating Margin | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% | 0.29% | -2.7% | 1.4% | 0.09% | 1.6% | 2.0% | 2.1% | |
| Net Margin | 0.67% | 0.70% | 0.38% | 0.13% | -0.51% | 0.38% | -2.4% | 0.94% | 0.19% | · | 1.2% | 1.2% | |
| Pretax Margin | 0.86% | 0.94% | 0.53% | 0.31% | -0.42% | 0.20% | -2.5% | 1.2% | -0.17% | 1.5% | 1.9% | 1.9% | |
| EBITDA Margin | 1.4% | 1.4% | 0.86% | 0.69% | 0.05% | 0.77% | -2.1% | 2.1% | 0.85% | 2.2% | 2.5% | 2.5% | |
| ROA | 3.1% | 3.2% | 1.9% | 0.60% | -2.1% | 1.4% | -9.0% | 3.4% | 0.64% | · | 4.4% | 4.3% | |
| ROE | -60.5% | -52.1% | -27.6% | -14.7% | -172.5% | 34.1% | -91.1% | 22.0% | 4.0% | · | 22.3% | 19.2% | |
| ROIC | -71.1% | -61.1% | -27.5% | -10.5% | 101.9% | 49.9% | -224.3% | 25.4% | -2.4% | 18.6% | 23.6% | 21.3% |
Liquidez y Solvencia
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.3 | |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.7 | 0.5 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.1 | 0.0 | · | |
| Interest Coverage | 7.5 | 10.6 | 24.4 | 7.8 | -4.0 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 | 13.8 | 15.3 |
Eficiencia
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.6 | 4.5 | 5.1 | 4.7 | 4.1 | 3.8 | 3.7 | 3.6 | 3.4 | 3.5 | 3.8 | 3.7 | |
| Inventory Turnover | 14.3 | 13.5 | 14.1 | 12.5 | 11.6 | 11.2 | 11.2 | 11.0 | 11.0 | 11.3 | 11.6 | 11.1 | |
| Receivables Turnover | 18.8 | 17.6 | 19.6 | 18.7 | 18.4 | 18.7 | 18.3 | 17.9 | 17.3 | 16.8 | 17.5 | 17.2 |
Por Acción
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $1072.78 | $919.74 | $918.33 | $782.49 | $650.05 | $552.61 | $521.92 | $483.50 | $434.31 | $406.18 | $368.32 | $306.06 | |
| Cash Flow / Share | $21.83 | $9.90 | $15.23 | $10.84 | $11.19 | $8.26 | $6.69 | $9.04 | $8.79 | $3.70 | $9.00 | $7.58 | |
| Dividend Paid / Share | $2.04 | $2.02 | $2.00 | $1.98 | $1.96 | $1.94 | $1.92 | $1.91 | $1.85 | $1.80 | $1.55 | $1.37 | |
| EPS (TTM) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 |
Tasas de Crecimiento
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 14.2% | -1.9% | 10.7% | 13.0% | 11.6% | 6.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.4% | 7.1% | 11.8% | 10.3% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | 7.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 12.1% | 87.0% | 173.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 79.0% | · | 18.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 9.8% | 83.2% | 158.2% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | 11.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | -3.0% | -2.8% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Net Income TTM | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| P/E | 32.9 | 26.0 | 28.5 | 75.1 | -15.5 | 27.4 | -4.1 | 10.4 | 60.3 | 19.3 | 18.1 | 23.1 | |
| Earnings Yield | 3.0% | 3.8% | 3.5% | 1.3% | -6.5% | 3.6% | -24.2% | 9.6% | 1.7% | 5.2% | 5.5% | 4.3% | |
| Payout Ratio | 28.6% | 31.6% | 58.6% | 201.1% | -59.9% | 93.8% | -15.4% | 42.3% | 226.9% | · | 35.9% | 37.9% | |
| Annual Payout | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M |
Estado de resultados
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.67B | $60.94B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.87B | $54.87B | $57.44B | $54.65B | $53.42B | $50.50B | $51.47B | $49.59B | |
| Cost of Revenue | $61.11B | $58.44B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.98B | $52.93B | $55.59B | $52.91B | $51.61B | $48.69B | $49.78B | $48.00B | |
| Gross Profit | $2.56B | $2.50B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.88B | $1.94B | $1.85B | $1.74B | $1.81B | $1.81B | $1.68B | $1.60B | |
| SG&A Expense | $1.62B | $1.54B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.28B | $1.27B | $1.27B | $1.19B | $1.23B | $1.17B | $1.18B | $1.20B | |
| Operating Income | $729M | $509M | $707M | $668M | $428M | $730M | $549M | $568M | $401M | $369M | $505M | $-32M | $162M | $604M | $-86M | $123M | |
| Interest Expense | · | · | $88M | $80M | $74M | $74M | $35M | $32M | $9M | $28M | $3M | $11M | $6M | $26M | $24M | $24M | |
| Other Non-op | $26M | $-16M | $11M | $10M | $30M | $9M | $-3M | $5M | $-1M | $1M | $10M | $-1M | $-10M | $-2M | $6M | $-3M | |
| Pretax Income | $554M | $392M | $630M | $598M | $384M | $665M | $511M | $541M | $391M | $342M | $512M | $-44M | $146M | $576M | $-104M | $96M | |
| Income Tax | $154M | $12M | $159M | $144M | $141M | $157M | $110M | $124M | $158M | $80M | $143M | $-33M | $143M | $209M | $-27M | $-3M | |
| Net Income | $398M | $399M | $467M | $450M | $239M | $506M | $400M | $416M | $235M | $261M | $368M | $-12M | $5M | $365M | $-77M | $98M | |
| EPS (Basic) | · | · | · | $1.89 | · | · | · | $1.71 | · | $1.07 | $1.50 | $-0.05 | · | $1.43 | $-0.30 | $0.36 | |
| EPS (Diluted) | · | · | · | $1.88 | · | · | · | $1.70 | · | $1.07 | $1.50 | $-0.05 | · | $1.41 | $-0.30 | $0.36 | |
| Shares (Basic) | · | 235,000,000 | 236,000,000 | 238,000,000 | · | 240,000,000 | 242,000,000 | 243,000,000 | · | 243,000,000 | 245,000,000 | 249,000,000 | · | 256,000,000 | 261,000,000 | 271,000,000 | |
| Shares (Diluted) | · | 236,000,000 | 237,000,000 | 239,000,000 | · | 241,000,000 | 243,000,000 | 245,000,000 | · | 245,000,000 | 246,000,000 | 249,000,000 | · | 258,000,000 | 261,000,000 | 273,000,000 | |
| EBITDA | · | $757M | $941M | $901M | · | $730M | $549M | $750M | · | $367M | $482M | $158M | · | $572M | $-119M | $308M |
Balance general
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.94B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B | $3.72B | $4.59B | $3.85B | · | $3.99B | $3.65B | $3.49B | |
| Receivables | $13.81B | $13.65B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B | $11.57B | $11.79B | $11.27B | · | $10.99B | $11.42B | $11.04B | |
| Inventory | $17.30B | $18.01B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B | $17.28B | $18.45B | $16.99B | · | $16.62B | $17.26B | $15.89B | |
| Other Current Assets | $2.76B | $2.47B | $2.67B | $2.60B | $2.41B | $2.40B | $2.62B | $2.59B | $2.66B | $3.16B | $2.82B | $2.58B | · | $1.90B | $2.26B | $2.27B | |
| Current Assets | $38.75B | $38.06B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B | $35.73B | $37.66B | $34.69B | · | $33.50B | $34.60B | $32.70B | |
| PP&E (Net) | $3.03B | $2.93B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B | $2.47B | $2.45B | $2.44B | · | $2.36B | $2.34B | $2.34B | |
| PP&E (Gross) | $7.97B | · | · | · | $7.52B | · | · | · | $6.70B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $4.93B | · | · | · | $4.66B | · | · | · | $4.17B | · | · | · | · | · | · | · | |
| Goodwill | $11.44B | $11.41B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B | $4.79B | $4.02B | $4.03B | $4.61B | $5.00B | $4.99B | $5.67B | |
| Intangibles | $2.19B | $2.28B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B | $1.72B | $1.35B | $1.41B | · | $1.57B | $1.63B | $1.69B | |
| Other Non-current Assets | $1.88B | $2.00B | $2.00B | $1.75B | $1.71B | $1.60B | $1.25B | $1.23B | $1.26B | $1.17B | $1.10B | $1.15B | · | $951M | $927M | $985M | |
| Total Assets | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B | |
| Accounts Payable | $38.28B | $37.83B | $39.00B | $36.86B | $34.71B | $32.81B | $31.30B | $30.36B | $31.76B | $32.09B | $34.26B | $31.54B | · | $29.60B | $30.08B | $28.36B | |
| Current Liabilities | $43.90B | $41.99B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B | $36.31B | $38.29B | $35.06B | · | $32.50B | $33.21B | $31.56B | |
| Capital Leases | $861M | · | · | · | $654M | · | · | · | $400M | · | · | · | · | · | · | · | |
| Common Stock | $2.89B | $2.81B | $2.85B | $2.75B | $2.96B | $2.95B | $2.93B | $2.83B | $2.92B | $2.89B | $2.85B | $2.73B | · | $2.82B | $2.75B | $2.58B | |
| Retained Earnings | $2.01B | $1.73B | $1.46B | $1.12B | $783M | $664M | $283M | $14M | $-286M | $-289M | $-425M | $-654M | · | $-342M | $-560M | $-301M | |
| Treasury Stock | $7.61B | $7.22B | $7.03B | $6.58B | $6.37B | $6.38B | $6.03B | $5.96B | $5.68B | $5.70B | $5.72B | $5.40B | $4.91B | $4.55B | $4.25B | $3.88B | |
| AOCI | $-165M | $-161M | $-153M | $-159M | $-155M | $-176M | $-180M | $-155M | $-167M | $-160M | $-155M | $-165M | · | $-142M | $-146M | $-176M | |
| Stockholders' Equity | $-2.88B | $-2.83B | $-2.88B | $-2.88B | $-2.78B | $-2.95B | $-2.99B | $-3.28B | $-3.21B | $-3.27B | $-3.45B | $-3.49B | · | $-2.22B | $-2.21B | $-1.78B | |
| Liabilities + Equity | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B |
Flujo de Efectivo
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $241M | $248M | $234M | $233M | $209M | $207M | $192M | $182M | $186M | $177M | $175M | $172M | $176M | $175M | $170M | $171M | |
| Stock-based Comp | $58M | $129M | $87M | $93M | $153M | $31M | $30M | $30M | $33M | $31M | $28M | $29M | $27M | $21M | $25M | $23M | |
| Amort. of Intangibles | $95M | $95M | $84M | $87M | $89M | $77M | $69M | $68M | $73M | $64M | $63M | $64M | $70M | $69M | $71M | $71M | |
| Restructuring | $40M | $25M | $21M | $20M | $27M | $28M | $9M | $24M | $69M | $53M | $28M | $25M | $33M | $16M | $17M | $29M | |
| Other Non-cash | · | · | · | $197M | · | · | · | $-2.27B | · | · | · | $339M | · | · | · | $-281M | |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.52B | $2.92B | $-396M | $-1.65B | $2.08B | $-54M | $1.16B | $528M | $863M | $1.36B | $597M | $23M | |
| CapEx | $264M | $146M | $131M | $108M | $232M | $126M | $99M | $90M | $193M | $112M | $114M | $92M | $217M | $109M | $85M | $70M | |
| Investing Cash Flow | $-281M | $-181M | $-1.98B | $-142M | $-1.63B | $-2.90B | $-976M | $-88M | $166M | $-1.85B | $-105M | $-63M | $-206M | $-91M | $-87M | $-70M | |
| Debt Issued | $0 | $0 | $0 | $1.00B | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | $488M | · | · | · | $-9M | · | · | · | $-7M | · | · | · | $-7M | |
| Stock Repurchased | $350M | $250M | $383M | $375M | $0 | $375M | $15M | $375M | $0 | $0 | $250M | $500M | $500M | $250M | $250M | $1.00B | |
| Net Stock Activity | · | · | · | $-375M | · | · | · | $-375M | · | · | · | $-500M | · | · | · | $-1.00B | |
| Dividends Paid | $120M | $120M | $122M | $129M | $120M | $124M | $122M | $128M | $122M | $122M | $124M | $131M | $126M | $128M | $129M | $142M | |
| Financing Cash Flow | $-490M | $-483M | $-519M | $-110M | $663M | $-507M | $2.33B | $-540M | $-859M | $1.03B | $-353M | $-666M | $-592M | $-934M | $-362M | $-1.16B | |
| Net Change in Cash | $919M | $1.16B | $-1.82B | $719M | $548M | $-484M | $943M | $-2.27B | $1.39B | $-878M | $710M | $-206M | $58M | $336M | $162M | $-1.23B | |
| Free Cash Flow | · | · | · | $865M | · | · | · | $-1.74B | · | · | · | $453M | · | · | · | $-47M | |
| Levered FCF | · | · | · | $804M | · | · | · | $-1.76B | · | · | · | $456M | · | · | · | $-72M |
Rentabilidad
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 4.1% | 3.6% | 3.6% | · | 3.9% | 3.5% | 3.6% | · | 3.5% | 3.2% | 3.2% | · | 3.5% | 3.2% | 3.2% | |
| Operating Margin | · | 0.84% | 1.1% | 1.0% | · | 1.3% | 0.99% | 1.1% | · | 0.67% | 0.84% | -0.03% | · | 1.1% | -0.23% | 0.28% | |
| Net Margin | · | 0.65% | 0.71% | 0.70% | · | 0.92% | 0.72% | 0.80% | · | 0.47% | 0.61% | 0.01% | · | 0.68% | -0.25% | 0.22% | |
| Pretax Margin | · | 0.64% | 0.96% | 0.93% | · | 1.2% | 0.92% | 1.0% | · | 0.62% | 0.85% | -0.05% | · | 1.1% | -0.27% | 0.22% | |
| EBITDA Margin | · | 1.2% | 1.4% | 1.4% | · | 1.3% | 0.99% | 1.4% | · | 0.67% | 0.84% | 0.29% | · | 1.1% | -0.23% | 0.62% | |
| ROA | · | 0.75% | 0.89% | 0.92% | · | 1.1% | 0.85% | 0.96% | · | 0.58% | 0.78% | 0.01% | · | 0.81% | -0.29% | 0.25% | |
| ROE | · | -13.8% | -15.9% | -14.6% | · | -16.3% | -12.4% | -12.3% | · | -9.4% | -12.5% | -0.19% | · | -23.6% | 21.4% | -56.7% | |
| ROIC | · | -17.4% | -18.3% | -17.6% | · | -18.9% | -14.4% | -13.4% | · | -8.5% | -10.1% | -0.09% | · | -16.4% | 5.1% | -7.8% |
Liquidez y Solvencia
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 0.9 | 1.0 | · | 0.9 | 1.0 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | |
| Quick Ratio | · | 0.4 | 0.4 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | 8.0 | 8.3 | · | 9.9 | 15.7 | 17.8 | · | 11.1 | 60.2 | -1.0 | · | 20.4 | -4.8 | 5.5 |
Eficiencia
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 1.1 | 1.2 | 1.3 | · | 1.1 | 1.2 | 1.2 | · | 1.2 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | |
| Inventory Turnover | · | 3.4 | 3.4 | 3.7 | · | 3.2 | 3.0 | 3.1 | · | 3.1 | 3.1 | 3.2 | · | 3.0 | 3.1 | 3.1 | |
| Receivables Turnover | · | 4.6 | 5.0 | 5.0 | · | 4.5 | 4.6 | 4.5 | · | 4.9 | 5.0 | 4.9 | · | 4.8 | 4.9 | 4.9 |
Por Acción
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $258.22 | $276.91 | $267.82 | · | $227.71 | $227.42 | $213.38 | · | $224.13 | $233.52 | $219.05 | · | $195.69 | $197.20 | $181.70 | |
| Cash Flow / Share | · | · | · | $4.07 | · | · | · | $-6.72 | · | · | · | $2.18 | · | · | · | $0.08 | |
| Dividend / Share | · | $0.51 | $0.51 | $0.51 | · | $0.51 | $0.51 | $0.51 | · | $0.50 | $0.50 | $0.50 | · | $0.50 | $0.50 | $0.50 |
Valoración (TTM)
| Métrica | Tendencia | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $250.74B | $244.67B | $234.31B | · | $222.29B | $222.28B | $224.45B | · | $220.38B | $216.01B | $210.04B | · | $198.62B | $192.96B | $186.95B | |
| Net Income TTM | · | $1.55B | $1.66B | $1.59B | · | $1.56B | $1.31B | $1.28B | · | $622M | $726M | $281M | · | $519M | $-1.24B | $-1.11B | |
| Payout Ratio | · | · | · | 28.7% | · | · | · | 30.8% | · | · | · | 2620.0% | · | · | · | 129.1% | |
| Annual Payout | · | $491M | $495M | $495M | · | $496M | $494M | $496M | · | $503M | $509M | $514M | · | $533M | $541M | $552M |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Ingresos | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| Margen Bruto % | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% |
| Margen Operativo % | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% |
| Beneficio neto | $1.71B | $1.56B | $852M | $330M | $-938M |
| EPS Diluido | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 |
| Métrica | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Ratio corriente | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 |
| Ratio Rápido | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
| Métrica | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Flujo de caja libre | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B |
Propietarios institucionales (13F) 1 605 declarantes · $54.4B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 156 (-26 vs trimestre anterior) | 81 (-19 vs trimestre anterior) | 530 (-24 vs trimestre anterior) | 574 (+58 vs trimestre anterior) | +7.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6 461 178 523 | 31 441 258 | 11,88% | Acciones |
| BlackRock, Inc. | $6 293 114 912 | 26 490 633 | 11,57% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $3 632 811 706 | 15 292 186 | 6,68% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $3 530 205 977 | 14 860 271 | 6,49% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3 258 822 899 | 13 717 894 | 5,99% | Acciones |
| STATE STREET CORP | $2 842 909 265 | 11 967 121 | 5,23% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $1 531 751 894 | 6 472 810 | 2,82% | Acciones |
| Invesco Ltd. | $1 126 646 236 | 4 742 576 | 2,07% | Acciones |
| MORGAN STANLEY | $1 098 793 649 | 4 625 329 | 2,02% | Acciones |
| WCM INVESTMENT MANAGEMENT, LLC | $971 445 537 | 4 112 461 | 1,79% | Acciones |
| NORGES BANK | $885 248 810 | 3 726 422 | 1,63% | Acciones |
| BANK OF AMERICA CORP /DE/ | $689 065 528 | 2 900 596 | 1,27% | Acciones |
| NORTHERN TRUST CORP | $681 536 598 | 2 868 903 | 1,25% | Acciones |
| JPMORGAN CHASE & CO | $630 412 357 | 2 668 749 | 1,16% | Acciones |
| GOLDMAN SACHS GROUP INC | $566 588 458 | 2 385 033 | 1,04% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $499 624 076 | 2 103 149 | 0,92% | Acciones |
| FMR LLC | $490 857 853 | 2 066 248 | 0,90% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $490 754 373 | 2 322 438 | 0,90% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $469 793 667 | 1 977 579 | 0,86% | Acciones |
| Legal & General Group Plc | $438 869 762 | 1 847 406 | 0,81% | Acciones |
| AQR CAPITAL MANAGEMENT LLC | $411 645 774 | 1 732 808 | 0,76% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $369 172 278 | 1 554 017 | 0,68% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $315 702 986 | 1 328 940 | 0,58% | Acciones |
| AMERIPRISE FINANCIAL INC | $311 391 613 | 1 310 794 | 0,57% | Acciones |
| NORDEA INVESTMENT MANAGEMENT AB | $308 748 216 | 1 297 534 | 0,57% | Acciones |
| Bank of New York Mellon Corp | $308 639 982 | 1 299 209 | 0,57% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $281 612 012 | 1 185 468 | 0,52% | Acciones |
| Robeco Institutional Asset Management B.V. | $258 918 781 | 1 089 909 | 0,48% | Acciones |
| DEUTSCHE BANK AG\ | $238 933 097 | 1 005 780 | 0,44% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $230 523 823 | 970 390 | 0,42% | Acciones |
| JANE STREET GROUP, LLC | $225 610 732 | 949 700 | 0,41% | Opción de venta |
| Man Group plc | $222 013 123 | 934 556 | 0,41% | Acciones |
| WELLS FARGO & COMPANY/MN | $219 711 690 | 924 868 | 0,40% | Acciones |
| UBS Group AG | $218 780 954 | 920 950 | 0,40% | Acciones |
| Amundi | $211 809 683 | 891 605 | 0,39% | Acciones |
| Nuveen, LLC | $211 731 009 | 891 274 | 0,39% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $203 800 043 | 857 888 | 0,37% | Acciones |
| ProShare Advisors LLC | $197 187 154 | 830 052 | 0,36% | Acciones |
| ROYAL BANK OF CANADA | $185 518 000 | 780 931 | 0,34% | Acciones |
| BARCLAYS PLC | $177 344 480 | 746 525 | 0,33% | Acciones |
| FEDERATED HERMES, INC. | $176 399 992 | 742 549 | 0,32% | Acciones |
| SEI INVESTMENTS CO | $173 413 944 | 729 965 | 0,32% | Acciones |
| JANE STREET GROUP, LLC | $169 712 864 | 714 400 | 0,31% | Opción de compra |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $163 869 121 | 693 714 | 0,30% | Acciones |
| Allianz Asset Management GmbH | $163 833 492 | 689 651 | 0,30% | Acciones |
| Swedbank AB | $159 718 953 | 672 331 | 0,29% | Acciones |
| Swiss National Bank | $157 644 816 | 663 600 | 0,29% | Acciones |
| JANUS HENDERSON GROUP PLC | $155 390 858 | 735 467 | 0,29% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $141 722 832 | 596 577 | 0,26% | Acciones |
| 1832 Asset Management L.P. | $139 039 117 | 585 280 | 0,26% | Acciones |
Activistas y propietarios del %+ 5 3 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Cardinal Health, Inc. ×2 presentaciones | 5 de junio de 2014 | · | Presentación inicial | · | SEC |
| Persona informante no revelada | 2 de julio de 2004 | · | Presentación inicial | · | SEC |
| Persona informante no revelada | 28 de mayo de 2004 | · | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 84 insiders · 45 directivos · 37 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Jason M. Hollar | Chief Executive Officer | 19 de agosto de 2026 S | 190 603 | 0 | 10 | $-29 375 516 |
| Deborah Weitzman | CEO, PSS Segment | 18 de agosto de 2026 S | 77 901 | 0 | 3 | $-1 731 524 |
| Stephen M Mason | CEO, GMPD Segment | 18 de agosto de 2026 S | 18 061 | 0 | 4 | $-8 274 118 |
| Michael C Kaufmann | CEO | 15 de agosto de 2022 M | 601 065 | 0 | 0 | $0 |
| Victor L. Crawford | CEO, Pharmaceutical Segment | 15 de agosto de 2022 F | 105 699 | 0 | 0 | $0 |
| Jon L Giacomin | CEO, Medical Segment | 15 de agosto de 2019 F | 61 387 | 0 | 0 | $0 |
| Donald M Casey Jr. | CEO, Medical Segment | 15 de septiembre de 2017 F | 146 503 | 0 | 0 | $0 |
| Michael A Lynch | CEO, Medical Segment | 27 de febrero de 2012 M | 89 204 | 0 | 0 | $0 |
| Kerry R Clark | Former Chairman and CEO | 1 de septiembre de 2009 A | 238 635 | 0 | 0 | $0 |
| Mark W Parrish | CEO - HSCS | 2 de septiembre de 2007 F | 68 041 | 0 | 0 | $0 |
| Ronald K Labrum | CEO-Supply Chain Svcs. | 16 de mayo de 2006 M | 36 082 | 0 | 0 | $0 |
| Joseph C Papa | Chmn & CEO, Pharm Techn & Svcs | 13 de diciembre de 2004 A | 14 400 | 0 | 0 | $0 |
| Aaron E Alt | Chief Financial Officer | 18 de agosto de 2026 S | 20 495 | 0 | 5 | $-10 451 104 |
| Jorge M Gomez | Chief Financial Officer | 8 de noviembre de 2018 F | 39 582 | 0 | 0 | $0 |
| Jeffrey William Henderson | Chief Financial Officer | 27 de agosto de 2014 M | 67 190 | 0 | 0 | $0 |
| Richard J Miller | EVP & CFO | 17 de noviembre de 2003 A | · | 0 | 0 | $0 |
| George L Fotiades | President & COO | 15 de enero de 2003 P | 80 278 | 0 | 0 | $0 |
| Mary C. Scherer | Chief Accounting Officer | 19 de agosto de 2026 S | 2 811 | 0 | 2 | $-546 473 |
| Michelle D. Greene | Chief Information Officer | 18 de agosto de 2026 S | 10 330 | 0 | 6 | $-3 373 574 |
| Jessica L Mayer | Chief Legal/Compliance Officer | 18 de agosto de 2026 S | 33 076 | 0 | 4 | $-6 952 485 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | 15 de agosto de 2026 F | 11 757 | 0 | 0 | $0 |
| Ola M Snow | Chief Human Resources Officer | 1 de diciembre de 2025 F | 15 111 | 0 | 0 | $0 |
| Patricia M English | Chief Accounting Officer | 15 de agosto de 2022 F | 9 000 | 0 | 0 | $0 |
| Brian S Rice | Chief Information Officer | 15 de agosto de 2022 F | 37 850 | 0 | 0 | $0 |
| Michele Holcomb | EVP - Strategy & Corp. Dev. | 15 de agosto de 2022 F | 44 491 | 0 | 0 | $0 |
| Stuart G Laws | SVP & Chief Accounting Officer | 15 de agosto de 2020 F | 12 289 | 0 | 0 | $0 |
| Craig S Morford | Chief Legal/Compliance Officer | 3 de diciembre de 2018 F | 126 301 | 0 | 0 | $0 |
| Patricia Morrison | Chief Information Officer | 31 de agosto de 2018 F | 30 725 | 0 | 0 | $0 |
| Pamela O. Kimmet | Chief Human Resources Officer | 15 de agosto de 2018 F | 22 612 | 0 | 0 | $0 |
| George S Barrett | Executive Chairman | 15 de agosto de 2018 F | 502 630 | 0 | 0 | $0 |
| Carole S Watkins | Chief HR Officer | 20 de mayo de 2016 M | 31 585 | 0 | 0 | $0 |
| Falk T Stephen | EVP, Gen. Counsel & Corp. Sec. | 30 de noviembre de 2015 G | 32 455 | 0 | 0 | $0 |
| Meghan Fitzgerald | EVP, Strategy & Health Policy | 17 de noviembre de 2015 F | 16 760 | 0 | 0 | $0 |
| Mark R Blake | EVP - Strategy & Corp. Dev. | 7 de noviembre de 2014 M | 20 409 | 0 | 0 | $0 |
| Ivan K Fong | CLO & Secretary | 1 de noviembre de 2008 F | 50 886 | 0 | 0 | $0 |
| Vivek Jain | EVP - Corp. Dev. & Strategy | 26 de septiembre de 2008 A | 39 594 | 0 | 0 | $0 |
| Daniel J Walsh | EVP, Chf Ethcs & Compl Offcr | 26 de noviembre de 2007 I | 1 740 | 0 | 0 | $0 |
| Eric Slusser | EVP, CAO & Controller | 4 de junio de 2007 M | 8 573 | 0 | 0 | $0 |
| Brendan A Ford | EVP-Corporate Development | 2 de septiembre de 2006 F | 85 978 | 0 | 0 | $0 |
| RUCCI ANTHONY J | EVP & Chief Admin. Officer | 6 de septiembre de 2005 G | 55 382 | 0 | 0 | $0 |
| Gary D Dolch | EVP - Quality & Reg. Affairs | 2 de septiembre de 2005 A | 6 137 | 0 | 0 | $0 |
| Jody R Davids | EVP & CIO | 2 de septiembre de 2005 A | 4 607 | 0 | 0 | $0 |
| Paul S Williams | EVP, CLO & Secretary | 17 de febrero de 2005 G | 7 000 | 0 | 0 | $0 |
| Gary S Jensen | SVP - Corporate Controller | 23 de agosto de 2004 A | 2 462 | 0 | 0 | $0 |
| Stephen S Thomas | EVP-Group Pres.-AIS | 24 de febrero de 2004 M | 31 039 | 0 | 0 | $0 |
| Hall Patricia Hemingway | Consejero | 15 de abril de 2026 A | 28 645 | 0 | 1 | $-918 880 |
| Michelle Brennan | Consejero | 5 de noviembre de 2025 A | 8 086 | 0 | 0 | $0 |
| Robert Azelby | Consejero | 5 de noviembre de 2025 A | 4 085 | 0 | 0 | $0 |
| Nancy Killefer | Consejero | 5 de noviembre de 2025 A | 27 624 | 0 | 0 | $0 |
| Akhil Johri | Consejero | 5 de noviembre de 2025 A | 22 868 | 0 | 0 | $0 |
| Sudhakar Ramakrishna | Consejero | 5 de noviembre de 2025 A | 2 116 | 0 | 0 | $0 |
| Sheri H. Edison | Consejero | 5 de noviembre de 2025 A | 14 848 | 0 | 0 | $0 |
| Christine Mundkur | Consejero | 5 de noviembre de 2025 A | 7 536 | 0 | 0 | $0 |
| Gregory B Kenny | Consejero | 5 de noviembre de 2025 A | 64 194 | 0 | 0 | $0 |
| Steven Barg | Consejero | 15 de noviembre de 2023 A | 4 739 | 0 | 0 | $0 |
| Sujatha Chandrasekaran | Consejero | 15 de noviembre de 2023 A | 4 739 | 0 | 0 | $0 |
| Bruce Downey | Consejero | 9 de noviembre de 2022 A | 53 929 | 0 | 0 | $0 |
| COX CARRIE SMITH | Consejero | 9 de noviembre de 2022 A | 41 631 | 0 | 0 | $0 |
| Dean A Scarborough | Consejero | 18 de octubre de 2022 A | 11 138 | 0 | 0 | $0 |
| John H Weiland | Consejero | 11 de noviembre de 2021 A | 11 138 | 0 | 0 | $0 |
| Michael J Losh | Consejero | 15 de octubre de 2021 A | 9 988 | 0 | 0 | $0 |
| Calvin Darden | Consejero | 9 de noviembre de 2020 A | 39 616 | 0 | 0 | $0 |
| Colleen F. Arnold | Consejero | 12 de noviembre de 2019 A | 35 103 | 0 | 0 | $0 |
| David J Anderson | Consejero | 16 de enero de 2018 A | 9 946 | 0 | 0 | $0 |
| David P King | Consejero | 8 de noviembre de 2017 A | 21 044 | 0 | 0 | $0 |
| Clayton M Jones | Consejero | 8 de mayo de 2017 S | 0 | 0 | 0 | $0 |
| NOTEBAERT RICHARD C | Consejero | 3 de marzo de 2015 M | 35 778 | 0 | 0 | $0 |
| John F Finn | Consejero | 5 de noviembre de 2014 A | 21 074 | 0 | 0 | $0 |
| Glenn Britt | Consejero | 7 de mayo de 2014 A | 18 314 | 0 | 0 | $0 |
| Jean G Spaulding | Consejero | 6 de noviembre de 2013 A | 17 182 | 0 | 0 | $0 |
| David W Raisbeck | Consejero | 2 de noviembre de 2011 A | 17 075 | 0 | 0 | $0 |
| James J Mongan MD | Consejero | 3 de noviembre de 2010 A | 7 150 | 0 | 0 | $0 |
| Philip L Francis | Consejero | 1 de septiembre de 2009 D | 1 021 | 0 | 0 | $0 |
| John B Mccoy | Consejero | 5 de noviembre de 2008 A | 2 721 | 0 | 0 | $0 |
| Robert D Walter | Consejero | 6 de octubre de 2008 M | 1 531 235 | 0 | 0 | $0 |
| Matthew D Walter | Consejero | 7 de enero de 2008 G | 2 232 | 0 | 0 | $0 |
| Robert L Gerbig | Consejero | 12 de febrero de 2007 M | 66 218 | 0 | 0 | $0 |
| John F Havens | Consejero | 8 de noviembre de 2006 A | 30 973 | 0 | 0 | $0 |
| David Bing | Consejero | 3 de agosto de 2005 A | 3 669 | 0 | 0 | $0 |
| Robert W Musslewhite | · | 5 de noviembre de 2025 A | 2 116 | 0 | 0 | $0 |
| David C Evans | · | 5 de noviembre de 2025 A | 15 373 | 0 | 0 | $0 |
| David L Schlotterbeck | · | 1 de septiembre de 2009 D | 61 523 | 0 | 0 | $0 |
| Michael D Ohalleran | · | 1 de septiembre de 2009 D | 8 458 | 0 | 0 | $0 |
| George N Conrades | · | 5 de noviembre de 2008 A | 2 653 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 148 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| PEZ · Invesco Exchange-Traded Fund Trust | 5,29% | 4 961 SH | 2 de octubre de 2026 | Diario |
| FXG · First Trust Exchange-Traded AlphaDE… | 3,15% | 31 414 NS | 31 de julio de 2026 | N-PORT |
| STNC · Hennessy Funds Trust | 2,97% | 12 009 NS | 31 de julio de 2026 | N-PORT |
| IYK · iShares Trust | 2,56% | 150 019 SH | 11 de septiembre de 2026 | Diario |
| NUMV · Nushares ETF Trust | 2,30% | 44 435 NS | 31 de julio de 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 2,09% | 14 948 SH | 2 de octubre de 2026 | Diario |
| SMRI · EA Series Trust | 1,84% | 51 638 NS | 31 de julio de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,59% | 59 923 SH | 2 de octubre de 2026 | Diario |
| NULV · Nushares ETF Trust | 1,53% | 145 860 NS | 31 de julio de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,51% | 597 NS | 31 de julio de 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1,49% | 228 600 NS | 31 de julio de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,47% | 1 193 309 NS | 31 de julio de 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 1,34% | 23 570 SH | 19 de agosto de 2026 | Diario |
| UPSD · ETF Series Solutions | 1,31% | 6 646 NS | 31 de julio de 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 1,25% | 527 725 SH | 2 de octubre de 2026 | Diario |
| SRHQ · Elevation Series Trust | 1,20% | 11 056 NS | 31 de julio de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 1,11% | 6 347 SH | 2 de octubre de 2026 | Diario |
| RPV · Invesco Exchange-Traded Fund Trust | 1,10% | 79 806 SH | 2 de octubre de 2026 | Diario |
| ESMV · iShares Trust | 1,06% | 350 SH | 11 de septiembre de 2026 | Diario |
| PDP · Invesco Exchange-Traded Fund Trust | 1,06% | 67 986 SH | 2 de octubre de 2026 | Diario |
| VOE · VANGUARD INDEX FUNDS | 0,96% | 1 504 470 SH | 19 de agosto de 2026 | Diario |
| ABFL · Abacus FCF ETF Trust | 0,92% | 21 099 NS | 31 de julio de 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,87% | 4 124 NS | 31 de julio de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,82% | 707 389 SH | 19 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,78% | 111 939 NS | 31 de julio de 2026 | N-PORT |
| IWP · iShares Trust | 0,74% | 604 324 SH | 11 de septiembre de 2026 | Diario |
| LSEQ · Harbor ETF Trust | 0,70% | 468 NS | 31 de julio de 2026 | N-PORT |
| IXJ · iShares Trust | 0,70% | 123 272 SH | 11 de septiembre de 2026 | Diario |
| CURE · Direxion Shares ETF Trust | 0,62% | 4 609 NS | 31 de julio de 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,59% | 4 662 NS | 31 de julio de 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,55% | 31 604 NS | 31 de julio de 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,54% | 5 075 476 SH | 19 de agosto de 2026 | Diario |
| FTLS · First Trust Exchange-Traded Fund III | 0,51% | 54 815 NS | 31 de julio de 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,47% | 19 654 SH | 2 de octubre de 2026 | Diario |
| LGDX · Tidal Trust III | 0,44% | 2 735 NS | 31 de julio de 2026 | N-PORT |
| EVUS · iShares Trust | 0,43% | 6 970 SH | 11 de septiembre de 2026 | Diario |
| RECS · Columbia ETF Trust I | 0,43% | 108 869 NS | 31 de julio de 2026 | N-PORT |
| IMCG · iShares Trust | 0,42% | 71 722 SH | 11 de septiembre de 2026 | Diario |
| QLC · FlexShares Trust | 0,42% | 18 368 NS | 31 de julio de 2026 | N-PORT |
| IWR · iShares Trust | 0,41% | 959 539 SH | 11 de septiembre de 2026 | Diario |
| LCOW · Pacer Funds Trust | 0,40% | 454 NS | 31 de julio de 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,39% | 11 919 NS | 31 de julio de 2026 | N-PORT |
| IMCB · iShares Trust | 0,39% | 27 470 SH | 11 de septiembre de 2026 | Diario |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,36% | 7 324 NS | 31 de julio de 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,36% | 5 200 NS | 31 de julio de 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,36% | 7 082 NS | 31 de julio de 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,35% | 445 000 | 2 de octubre de 2026 | Diario |
| IMCV · iShares Trust | 0,35% | 16 989 SH | 11 de septiembre de 2026 | Diario |
| ACWV · iShares, Inc. | 0,33% | 46 363 SH | 11 de septiembre de 2026 | Diario |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,32% | 9 479 000 | 2 de octubre de 2026 | Diario |
| XOEF · iShares Trust | 0,31% | 293 SH | 11 de septiembre de 2026 | Diario |
| IWS · iShares Trust | 0,29% | 189 265 SH | 11 de septiembre de 2026 | Diario |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,28% | 30 714 NS | 31 de julio de 2026 | N-PORT |
| GLOF · iShares Trust | 0,28% | 2 389 SH | 11 de septiembre de 2026 | Diario |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,28% | 12 847 000 | 2 de octubre de 2026 | Diario |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,27% | 6 869 NS | 31 de julio de 2026 | N-PORT |
| ESGU · iShares Trust | 0,26% | 200 383 SH | 11 de septiembre de 2026 | Diario |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,26% | 17 795 NS | 31 de julio de 2026 | N-PORT |
| NULC · Nushares ETF Trust | 0,26% | 796 NS | 31 de julio de 2026 | N-PORT |
| CATH · Global X Funds | 0,26% | 14 490 NS | 31 de julio de 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 0,25% | 7 970 000 | 2 de octubre de 2026 | Diario |
| DYNF · BlackRock ETF Trust | 0,25% | 443 705 SH | 11 de septiembre de 2026 | Diario |
| VFMO · VANGUARD WELLINGTON FUND | 0,25% | 21 158 SH | 19 de agosto de 2026 | Diario |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,24% | 1 323 136 SH | 19 de agosto de 2026 | Diario |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,23% | 233 192 SH | 2 de octubre de 2026 | Diario |
| VYM · VANGUARD WHITEHALL FUNDS | 0,23% | 934 496 SH | 19 de agosto de 2026 | Diario |
| ESG · FlexShares Trust | 0,23% | 1 320 NS | 31 de julio de 2026 | N-PORT |
| SIZE · iShares Trust | 0,22% | 3 988 SH | 11 de septiembre de 2026 | Diario |
| LRGF · iShares Trust | 0,22% | 33 556 SH | 11 de septiembre de 2026 | Diario |
| VTV · VANGUARD INDEX FUNDS | 0,21% | 2 225 442 SH | 19 de agosto de 2026 | Diario |
| VFMF · VANGUARD WELLINGTON FUND | 0,21% | 6 281 SH | 19 de agosto de 2026 | Diario |
| EUSA · iShares, Inc. | 0,20% | 16 612 SH | 11 de septiembre de 2026 | Diario |
| PFM · Invesco Exchange-Traded Fund Trust | 0,20% | 6 670 SH | 2 de octubre de 2026 | Diario |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 813 183 SH | 2 de octubre de 2026 | Diario |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,19% | 53 931 SH | 19 de agosto de 2026 | Diario |
| IVE · iShares Trust | 0,19% | 388 621 SH | 11 de septiembre de 2026 | Diario |
| IUSV · iShares Trust | 0,18% | 205 310 SH | 11 de septiembre de 2026 | Diario |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,18% | 6 098 SH | 2 de octubre de 2026 | Diario |
| IQSU · New York Life Investments ETF Trust | 0,17% | 2 435 NS | 31 de julio de 2026 | N-PORT |
| CHRI · Global X Funds | 0,16% | 57 NS | 31 de julio de 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,16% | 4 467 000 | 2 de octubre de 2026 | Diario |
| DSI · iShares Trust | 0,16% | 35 796 SH | 11 de septiembre de 2026 | Diario |
| EGLE · Global X Funds | 0,13% | 12 NS | 31 de julio de 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0,12% | 6 NS | 31 de julio de 2026 | N-PORT |
| LQAI · Exchange Listed Funds Trust | 0,12% | 12 NS | 31 de julio de 2026 | N-PORT |
| DGRO · iShares Trust | 0,12% | 217 268 SH | 11 de septiembre de 2026 | Diario |
| VFVA · VANGUARD WELLINGTON FUND | 0,11% | 3 797 SH | 19 de agosto de 2026 | Diario |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,10% | 7 530 SH | 2 de octubre de 2026 | Diario |
| TOPC · iShares Trust | 0,10% | 144 SH | 11 de septiembre de 2026 | Diario |
| ACVF · ETF Opportunities Trust | 0,10% | 675 NS | 31 de julio de 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,10% | 52 911 SH | 19 de agosto de 2026 | Diario |
| DFSU · Dimensional ETF Trust | 0,10% | 9 417 NS | 31 de julio de 2026 | N-PORT |
| ILCG · iShares Trust | 0,10% | 12 549 SH | 11 de septiembre de 2026 | Diario |
| XVV · iShares Trust | 0,09% | 2 689 SH | 11 de septiembre de 2026 | Diario |
| USMV · iShares Trust | 0,09% | 91 385 SH | 11 de septiembre de 2026 | Diario |
| VOO · VANGUARD INDEX FUNDS | 0,09% | 6 082 026 SH | 19 de agosto de 2026 | Diario |
| VV · VANGUARD INDEX FUNDS | 0,09% | 273 537 SH | 19 de agosto de 2026 | Diario |
| XRMI · Global X Funds | 0,09% | 194 NS | 31 de julio de 2026 | N-PORT |
| XYLG · Global X Funds | 0,09% | 244 NS | 31 de julio de 2026 | N-PORT |
| XYLD · Global X Funds | 0,09% | 12 239 NS | 31 de julio de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,08% | 45 685 NS | 31 de julio de 2026 | N-PORT |
| IVV · iShares Trust | 0,08% | 2 952 119 SH | 11 de septiembre de 2026 | Diario |
| PTLC · Pacer Funds Trust | 0,08% | 11 916 NS | 31 de julio de 2026 | N-PORT |
| XCLR · Global X Funds | 0,08% | 13 NS | 31 de julio de 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 32 252 NS | 31 de julio de 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,08% | 21 NS | 31 de julio de 2026 | N-PORT |
| ILCB · iShares Trust | 0,08% | 4 535 SH | 11 de septiembre de 2026 | Diario |
| VOTE · TCW ETF Trust | 0,08% | 3 959 NS | 31 de julio de 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,08% | 1 385 SH | 2 de octubre de 2026 | Diario |
| BKLC · BNY Mellon ETF Trust | 0,08% | 19 424 NS | 31 de julio de 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,08% | 40 564 SH | 2 de octubre de 2026 | Diario |
| XTR · Global X Funds | 0,08% | 17 NS | 31 de julio de 2026 | N-PORT |
| IWD · iShares Trust | 0,08% | 282 063 SH | 11 de septiembre de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,08% | 7 436 156 SH | 19 de agosto de 2026 | Diario |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,08% | 38 624 SH | 19 de agosto de 2026 | Diario |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,08% | 76 610 SH | 19 de agosto de 2026 | Diario |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 169 890 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,08% | 19 715 SH | 19 de agosto de 2026 | Diario |
| TOV · EA Series Trust | 0,08% | 913 NS | 31 de julio de 2026 | N-PORT |
| IWB · iShares Trust | 0,08% | 162 672 SH | 11 de septiembre de 2026 | Diario |
| IYY · iShares Trust | 0,08% | 10 064 SH | 11 de septiembre de 2026 | Diario |
| DFUS · Dimensional ETF Trust | 0,08% | 71 472 NS | 31 de julio de 2026 | N-PORT |
| USCL · iShares Trust | 0,08% | 9 352 SH | 11 de septiembre de 2026 | Diario |
| SPUU · Direxion Shares ETF Trust | 0,08% | 884 NS | 31 de julio de 2026 | N-PORT |
| IWF · iShares Trust | 0,08% | 402 774 SH | 11 de septiembre de 2026 | Diario |
| QDPL · Pacer Funds Trust | 0,08% | 5 627 NS | 31 de julio de 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,08% | 32 168 SH | 2 de octubre de 2026 | Diario |
| IWV · iShares Trust | 0,08% | 64 328 SH | 11 de septiembre de 2026 | Diario |
| ITOT · iShares Trust | 0,08% | 304 905 SH | 11 de septiembre de 2026 | Diario |
| ILCV · iShares Trust | 0,07% | 4 083 SH | 11 de septiembre de 2026 | Diario |
| TILT · FlexShares Trust | 0,07% | 6 802 NS | 31 de julio de 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,07% | 183 SH | 2 de octubre de 2026 | Diario |
| DCOR · Dimensional ETF Trust | 0,07% | 9 717 NS | 31 de julio de 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,07% | 1 627 NS | 31 de julio de 2026 | N-PORT |
| TOK · iShares Trust | 0,07% | 656 SH | 11 de septiembre de 2026 | Diario |
| SPXL · Direxion Shares ETF Trust | 0,06% | 18 311 NS | 31 de julio de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,06% | 129 668 NS | 31 de julio de 2026 | N-PORT |
| URTH · iShares, Inc. | 0,06% | 20 873 SH | 11 de septiembre de 2026 | Diario |
| ACWI · iShares Trust | 0,05% | 74 784 SH | 11 de septiembre de 2026 | Diario |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,05% | 197 885 SH | 19 de agosto de 2026 | Diario |
| DXUV · Dimensional ETF Trust | 0,01% | 343 NS | 31 de julio de 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 40 400 | 30 de septiembre de 2026 | Diario |
| GTOS · Invesco Actively Managed Exchange-T… | 0,00% | 600 | 30 de septiembre de 2026 | Diario |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 de julio de 2026 | Diario |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 de julio de 2026 | Diario |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 de julio de 2026 | Diario |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 de julio de 2026 | Diario |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 de julio de 2026 | Diario |
CAH Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
Precio objetivo a 12 meses
15 analistas · 2026-10-02Objetivo medio $270.33 +18,4%
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| CAH | · | 32.9 | 14.2% | 0.67% | -60.5% | 3.8% |
| MCK | $242.30B | 22.5 | 12.4% | 1.2% | -224.3% | 3.6% |
| COR | $60.61B | 39.3 | 9.3% | 0.48% | 144.3% | 3.6% |
| HSIC | $8.81B | 23.3 | 4.0% | 3.0% | 12.0% | 31.1% |
| AHCO | $1.35B | -19.2 | -0.49% | -2.2% | -4.6% | · |
| ACH | · | · | · | · | · | · |
| MEDS | · | · | · | · | · | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.